Biolevate Raises €30 Million to Boost Life Sciences AI
Biolevate, a Paris-based company focused on accelerating advancements in life sciences through AI, has announced a successful Series A funding round, raising €30 million. The funding was led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund (MGHIF), Station F, and EQT Ventures.
Company Background
Biolevate aims to empower people by advancing life sciences through artificial intelligence. Co-founded by Anas Laaroussi, who serves as the CTO, and Joel Belafa, the CEO, the company is dedicated to transforming the life sciences sector by integrating cutting-edge AI technologies.
Strategic Use of Funds
The newly acquired funds are earmarked for several key initiatives. Biolevate plans to accelerate its international expansion and deepen its product capabilities. The company also intends to scale its deployments with life sciences organizations, allowing for broader application of its AI solutions across different markets.
Investor Involvement
The funding round saw significant interest from prominent investors. Leading the investment were RAISE France and Orange Ventures, with additional backing from MSD Global Health Innovation Fund (MGHIF), Station F, and EQT Ventures. This diverse group of investors underscores the confidence in Biolevate's potential to innovate within the life sciences sector.
Leadership Comments
Joel Belafa, co-founder and CEO of Biolevate, expressed optimism about the company’s future. He noted that the funding will enable Biolevate to "enhance our AI capabilities and extend our reach globally," highlighting the strategic importance of this investment round.
With the Series A funding secured, Biolevate is poised to make significant strides in the application of AI within life sciences, promising to bring transformative solutions to the industry.